Prinos
Panagiotis (Takis) Prinos

Team Leader - Epigenetics Cellular Screening

University of Toronto
takis.prinos@utoronto.ca

Panagiotis (Takis) completed his Ph.D. in Human Genetics and Developmental Biology from the University of Connecticut Health Center, Farmington, CT in 1998. After a post-doc on Molecular & Cellular Biology at IRCM in Montreal where he studied signaling pathways and control of gene expression during early embryonic development, he joined Aurelium BioPharma as senior scientist where he led the Cell Biology-Target Validation group from 2002-2006. During the next 5 years, he managed a Genome Canada project on the functional annotation of essential alternatively spliced isoforms in cancer at the Universite de Sherbrooke, Quebec. Subsequently, he directed the functional genomics/phenotypic platform at the Laboratory for Functional Genomics in Sherbrooke, Quebec. He joined the SGC in December 2014 where he is leading the Oncology patient-derived tumor cell screening activities.
Takis' current interests include cell-based assays and phenotypic screening, assay development and validation, HCS/HTS screens and epigenetic pathways in tumorigenesis, RNA splicing and metabolism, cell survival and proliferation.  

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH
Nat Chem Biol. 2022 . doi: 10.1038/s41589-022-01024-4
PMID: 35578032

PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB
Nat Commun. 2021 12(1):979. doi: 10.1038/s41467-021-21204-5
PMID: 33579912

Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
Ma T, Hu C, Lal B, Zhou W, Ma Y, Ying M, Prinos P, Quiñones-Hinojosa A, Lim M, Laterra J, Li Y
Cancer Res. 2021 81(9):2457-2469. doi: 10.1158/0008-5472.CAN-20-2489
PMID: 33574085

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH
Nat Commun. 2020 11(1):4205. doi: 10.1038/s41467-020-18020-8
PMID: 32826891

2023

3D Spheroid Invasion Assay for High-Throughput Screening of Small-Molecule Libraries.
Karve K, Poon S, Prinos P, Ailles L
Methods Mol Biol. 10.08.2023 2706:201-214. doi: 10.1007/978-1-0716-3397-7_15
PMID: 37558951

The identification of high-performing antibodies for transmembrane protein 106B (TMEM106B) for use in Western blot, immunoprecipitation, and immunofluorescence.
Ayoubi R, Fotouhi M, Southern K, Bhajiawala R, Fanti R, Prinos P, McPherson PS, Laflamme C
F1000Res. 07.08.2023 12:308. doi: 10.12688/f1000research.131333.1
PMID: 37545650

2022

PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L
Nat Rev Urol. 17.10.2022 . doi: 10.1038/s41585-022-00659-1
PMID: 36253570

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH
Nat Chem Biol. 16.05.2022 . doi: 10.1038/s41589-022-01024-4
PMID: 35578032

Post-transcriptional and Post-translational Modifications of Primary Cilia: How to Fine Tune Your Neuronal Antenna.
Rocha C, Prinos P
Front Cell Neurosci. 18.03.2022 16:809917. doi: 10.3389/fncel.2022.809917
PMID: 35295905

2021

Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
Ma T, Hu C, Lal B, Zhou W, Ma Y, Ying M, Prinos P, Quiñones-Hinojosa A, Lim M, Laterra J, Li Y
Cancer Res. 01.05.2021 81(9):2457-2469. doi: 10.1158/0008-5472.CAN-20-2489
PMID: 33574085

PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB
Nat Commun. 12.02.2021 12(1):979. doi: 10.1038/s41467-021-21204-5
PMID: 33579912

2020

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer.
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH
Nat Commun. 21.08.2020 11(1):4205. doi: 10.1038/s41467-020-18020-8
PMID: 32826891

Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.
Michealraj KA, Kumar SA, Kim LJY, Cavalli FMG, Przelicki D, Wojcik JB, Delaidelli A, Bajic A, Saulnier O, MacLeod G, Vellanki RN, Vladoiu MC, Guilhamon P, Ong W, Lee JJY, Jiang Y, Holgado BL, Rasnitsyn A, Malik AA, Tsai R, Richman CM, Juraschka K, Haapasalo J, Wang EY, De Antonellis P, Suzuki H, Farooq H, Balin P, Kharas K, Van Ommeren R, Sirbu O, Rastan A, Krumholtz SL, Ly M, Ahmadi M, Deblois G, Srikanthan D, Luu B, Loukides J, Wu X, Garzia L, Ramaswamy V, Kanshin E, Sánchez-Osuna M, El-Hamamy I, Coutinho FJ, Prinos P, Singh S, Donovan LK, Daniels C, Schramek D, Tyers M, Weiss S, Stein LD, Lupien M, Wouters BG, Garcia BA, Arrowsmith CH, Sorensen PH, Angers S, Jabado N, Dirks PB, Mack SC, Agnihotri S, Rich JN, Taylor MD
Cell. 20.05.2020 . doi: 10.1016/j.cell.2020.04.047
PMID: 32445698

2017

Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy.
Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, Park NI, Coutinho FJ, Whetstone H, Selvadurai HJ, Che C, Luu B, Carles A, Moksa M, Rastegar N, Head R, Dolma S, Prinos P, Cusimano MD, Das S, Bernstein M, Arrowsmith CH, Mungall AJ, Moore RA, Ma Y, Gallo M, Lupien M, Pugh TJ, Taylor MD, Hirst M, Eaves CJ, Simons BD, Dirks PB
Nature. 30.08.2017 . doi: 10.1038/nature23666
PMID: 28854171

ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells.
Park NI, Guilhamon P, Desai K, McAdam RF, Langille E, O'Connor M, Lan X, Whetstone H, Coutinho FJ, Vanner RJ, Ling E, Prinos P, Lee L, Selvadurai H, Atwal G, Kushida M, Clarke ID, Voisin V, Cusimano MD, Bernstein M, Das S, Bader G, Arrowsmith CH, Angers S, Huang X, Lupien M, Dirks PB
Cell Stem Cell. 11.07.2017 . doi: 10.1016/j.stem.2017.06.004
PMID: 28712938

2016

Chemical Biology Approaches for Characterization of Epigenetic Regulators.
Barsyte-Lovejoy D, Szewczyk MM, Prinos P, Lima-Fernandes E, Ackloo S, Arrowsmith CH
Meth. Enzymol.. 16.02.2016 574:79-103. doi: 10.1016/bs.mie.2016.01.011
PMID: 27423858

2015

Preclinical target validation using patient-derived cells.
Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M, Barker P, Barsyte D, Bengtson MH, Bell C, Bowness P, Boycott KM, Buser-Doepner C, Carpenter CL, Carr AJ, Clark K, Das AM, Dhanak D, Dirks P, Ellis J, Fantin VR, Flores C, Fon EA, Frail DE, Gileadi O, O'Hagan RC, Howe T, Isaac JT, Jabado N, Jakobsson PJ, Klareskog L, Knapp S, Lee WH, Lima-Fernandes E, Lundberg IE, Marshall J, Massirer KB, MacKenzie AE, Maruyama T, Mueller-Fahrnow A, Muthuswamy S, Nanchahal J, O'Brien C, Oppermann U, Ostermann N, Petrecca K, Pollock BG, Poupon V, Prinjha RK, Rosenberg SH, Rouleau G, Skingle M, Slutsky AS, Smith GA, Verhelle D, Widmer H, Young LT
Nat Rev Drug Discov. 20.02.2015 14(3):149-50. doi: 10.1038/nrd4565
PMID: 25722227

2014

Tumor microenvironment-associated modifications of alternative splicing
Brosseau, J-P, Lucier, J-F, Nwilati, H, Thibault, P, Garneau, D, Durand, M, Couture, S, Lapointe, E, Prinos, P, Klinck, R, Perreault, J-P, Chabot, B, Abou-Elela, S.
RNA. 02.2014 20(2):189-201. doi: 10.1261/rna.042168
PMID: 24335142

2013

MBNL1 and RBFOX2 cooperate to establish a splicing programme involved in pluripotent stem cell differentiation
Venables, JP, Lapasset, L, Gadea, G, Fort, P, Klinck, R, Irimia, M, Vignal, E, Thibault, P, Prinos, P, Chabot, B, Abou Elela, S, Roux, P, Lemaitre, J-M, Tazi, J.
Nat Commun. 2013 4:2480. doi: 10.1038/ncomms3480
PMID: 24048253

Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing
Shkreta L, Bell B, Revil T, Venables JP, Prinos P, Elela SA, Chabot B.
Cancer Treat Res. 2013 158:41-94. doi: 10.1007/978-3-642-31659-3_3
PMID: 24222354

RBFOX2 enforces the mesenchymal splicing signature in normal and cancer tissues
Venables, J, Brosseau, J-P, Gadea, G, Klinck, R, Prinos, P, Beaulieu, JF, Thibault, P, Tremblay, K, Rousset, F, Tazi, J, Abou Elela, S and Chabot, B.
Mol Cell Biol. 2013 33(2):396-405. doi:
PMID:

2012

Alternative splicing as a generator of functional diversity in cancer
Prinos, P, Klinck, R, Pereault, JP, Elela, SA, Chabot, B.
Med Sci. 11.15.2012 Vol. 1, 4, . doi:
PMID:

Proteins Associated with the Exon Junction Complex Also Control the Alternative Splicing of Apoptotic Regulators
Michelle L, Toutant J, Thibault P, Durand M, Garneau D, Lapointe E, Couture S, Le Hir H, Klinck R, Abou Elela S, Prinos P and Chabot B.
Mol Cell Biol. 03.15.2012 32(5):954-67. doi: 10.1128/MCB.06130-11
PMID: 22203037

2011

RNAi-mediated knockdown of α-enolase increases the sensitivity of tumor cells to antitubulin chemotherapeutics
Georges E, Bonneau AM, Prinos P
Int J Biochem Mol Biol. 2011 2(4):303-8. doi:
PMID: 22187664

Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity
Prinos P, Lacoste MC, Wong J, Bonneau AM, Georges, E.
Int J Biochem Mol Biol. 2011 2(1): 24-30. doi:
PMID: 21968505

SYK alternative splicing regulates mitosis and cancer cell survival
Prinos P, Garneau D, Lucier JF, Gendron D, Couture S, Boivin M, Brosseau JP, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault JP, Wellinger RJ, Elela SA.
Nat Struct Mol Biol. 06.18.2011 18(6):673-9. doi: 10.1038/nsmb.2040
PMID: 21552259

glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03